Our experienced medical team at the Center for SmartLipo recommends that patients verify their coverage directly with their insurance provider to determine eligibility, potential out-of-pocket costs, and whether any restrictions or special requirements apply
Builes-Montao has received consulting and speaking fees from Sanofi, Novo Nordisk, Novartis, Recordati Rare Diseases, Janssen, Chiesi, Abbott, and Boehringer Ingelheim, and is a shareholder of Festina Lente
Professional diabetes groups encourage individualized discussions between patients and their healthcare providers when considering newer medications during breastfeeding
Novo has also been pushing new formats and pricing as competition grows, including oral Wegovy options that could make the category easier to distribute and potentially easier to budget
It was specifically developed for the dietary management of type 2 diabetes and has a proof-of-concept randomized controlled trial supporting its A1C and glucose-lowering claims
Barent DuBois for shaping our discussions of exposure/response relationships
